GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000166710 | Endometrium | AEH | ameboidal-type cell migration | 90/2100 | 475/18723 | 3.73e-07 | 1.57e-05 | 90 |
GO:009013014 | Endometrium | AEH | tissue migration | 73/2100 | 365/18723 | 5.79e-07 | 2.20e-05 | 73 |
GO:009013214 | Endometrium | AEH | epithelium migration | 72/2100 | 360/18723 | 6.90e-07 | 2.55e-05 | 72 |
GO:001063114 | Endometrium | AEH | epithelial cell migration | 71/2100 | 357/18723 | 1.02e-06 | 3.52e-05 | 71 |
GO:00435428 | Endometrium | AEH | endothelial cell migration | 55/2100 | 279/18723 | 2.11e-05 | 4.15e-04 | 55 |
GO:19016539 | Endometrium | AEH | cellular response to peptide | 64/2100 | 359/18723 | 1.16e-04 | 1.63e-03 | 64 |
GO:004343410 | Endometrium | AEH | response to peptide hormone | 70/2100 | 414/18723 | 2.93e-04 | 3.35e-03 | 70 |
GO:00328699 | Endometrium | AEH | cellular response to insulin stimulus | 37/2100 | 203/18723 | 1.97e-03 | 1.54e-02 | 37 |
GO:00713758 | Endometrium | AEH | cellular response to peptide hormone stimulus | 49/2100 | 290/18723 | 2.24e-03 | 1.72e-02 | 49 |
GO:00434914 | Endometrium | AEH | protein kinase B signaling | 37/2100 | 211/18723 | 3.89e-03 | 2.64e-02 | 37 |
GO:00435342 | Endometrium | AEH | blood vessel endothelial cell migration | 32/2100 | 176/18723 | 3.97e-03 | 2.66e-02 | 32 |
GO:00082866 | Endometrium | AEH | insulin receptor signaling pathway | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:00328689 | Endometrium | AEH | response to insulin | 44/2100 | 264/18723 | 4.70e-03 | 3.00e-02 | 44 |
GO:000166716 | Endometrium | EEC | ameboidal-type cell migration | 91/2168 | 475/18723 | 7.87e-07 | 2.80e-05 | 91 |
GO:009013015 | Endometrium | EEC | tissue migration | 73/2168 | 365/18723 | 1.91e-06 | 5.78e-05 | 73 |
GO:009013215 | Endometrium | EEC | epithelium migration | 72/2168 | 360/18723 | 2.24e-06 | 6.59e-05 | 72 |
GO:001063115 | Endometrium | EEC | epithelial cell migration | 71/2168 | 357/18723 | 3.24e-06 | 8.85e-05 | 71 |
GO:190165314 | Endometrium | EEC | cellular response to peptide | 68/2168 | 359/18723 | 2.75e-05 | 4.83e-04 | 68 |
GO:004354213 | Endometrium | EEC | endothelial cell migration | 55/2168 | 279/18723 | 5.12e-05 | 8.18e-04 | 55 |
GO:004343416 | Endometrium | EEC | response to peptide hormone | 74/2168 | 414/18723 | 9.11e-05 | 1.28e-03 | 74 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0521417 | Esophagus | ESCC | Glioma | 52/4205 | 75/8465 | 4.20e-04 | 1.45e-03 | 7.43e-04 | 52 |
hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa049268 | Esophagus | ESCC | Relaxin signaling pathway | 81/4205 | 129/8465 | 1.72e-03 | 5.09e-03 | 2.61e-03 | 81 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0421114 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa052356 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa015227 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa052237 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa051425 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa052319 | Esophagus | ESCC | Choline metabolism in cancer | 61/4205 | 98/8465 | 7.97e-03 | 1.92e-02 | 9.84e-03 | 61 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3R3 | SNV | Missense_Mutation | | c.1103C>T | p.Ala368Val | p.A368V | Q92569 | protein_coding | deleterious(0.04) | probably_damaging(0.967) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PIK3R3 | SNV | Missense_Mutation | rs779089992 | c.280N>G | p.Thr94Ala | p.T94A | Q92569 | protein_coding | deleterious(0.02) | benign(0.072) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
PIK3R3 | SNV | Missense_Mutation | | c.977N>G | p.Leu326Arg | p.L326R | Q92569 | protein_coding | deleterious(0) | benign(0.038) | TCGA-E2-A15K-06 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PIK3R3 | SNV | Missense_Mutation | novel | c.499N>G | p.Gln167Glu | p.Q167E | Q92569 | protein_coding | tolerated(0.4) | benign(0.084) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
PIK3R3 | deletion | Frame_Shift_Del | | c.883delN | p.Met295Ter | p.M295* | Q92569 | protein_coding | | | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PIK3R3 | SNV | Missense_Mutation | novel | c.1304C>T | p.Thr435Ile | p.T435I | Q92569 | protein_coding | deleterious(0.01) | benign(0.083) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PIK3R3 | SNV | Missense_Mutation | novel | c.314G>A | p.Arg105Gln | p.R105Q | Q92569 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PIK3R3 | SNV | Missense_Mutation | novel | c.1010C>G | p.Ala337Gly | p.A337G | Q92569 | protein_coding | tolerated(0.49) | benign(0) | TCGA-C5-A2M1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PIK3R3 | SNV | Missense_Mutation | rs780117361 | c.116N>G | p.Pro39Arg | p.P39R | Q92569 | protein_coding | deleterious(0) | benign(0.36) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PIK3R3 | SNV | Missense_Mutation | | c.1015N>A | p.Glu339Lys | p.E339K | Q92569 | protein_coding | tolerated(0.12) | benign(0.06) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | GDC-0941 | PICTILISIB | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL1079593 | VS-5584 | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | XL-765 | VOXTALISIB | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL1234354 | PF-04691502 | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | BKM120 | BUPARLISIB | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL3360203 | PILARALISIB | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | BAY80-6946 | COPANLISIB | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL586701 | ZSTK-474 | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL2017974 | BUPARLISIB | |
8503 | PIK3R3 | KINASE, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL2165191 | AZD-6482 | |